BNT162b2 Vaccine Effective Against Severe COVID-19 in Adolescents
Two doses of the BNT162b2 vaccine are highly effective against COVID-19-related hospitalization and critical disease in adolescents aged 12 to 18 years.
Two doses of the BNT162b2 vaccine are highly effective against COVID-19-related hospitalization and critical disease in adolescents aged 12 to 18 years.
Dr Ryan Maves, CHEST COVID-19 Task Force Chair, talks about COVID-19-related triumphs of 2021, what clinicians can do now, and challenges for 2022.
Investigators assessed outcomes in patients with cirrhosis following receipt of the Pfizer or Moderna COVID-19 vaccine.
Large US companies have until Jan. 4, 2022, to ensure their employees are fully vaccinated against COVID-19, the Biden administration said.
Researchers assessed trends in COVID-19 vaccination, hospitalization, and mortality among individuals with schizophrenia.
One-quarter of U.S. parents report that their child has had to quarantine because of possible COVID-19 exposure since school started, a new poll reveals.
Some committee members said they also did not feel comfortable offering booster shots to young people who may not need them, when the risks of a third dose are unknown.
The US FDA approved Pfizer COVID-19 vaccine booster shots for people older than 65 years and for those at high risk for severe COVID-19.
Overall, 56.8 percent of health care personnel working at long-term care facilities (LTCFs) had completed COVID-19 vaccination through April 4, 2021.
These findings were consistent with a suggested reduction in vaccine protection against infection and continued protection against COVID-19-associated hospitalization and death.